SCNLF (Scancell Holdings) Net Margin %: 0.00% (As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Net Margin %?

Scancell Holdings SCNLF 20 Net Margin % is 0.00% as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, Scancell Holdings ranks worse than 52.64% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Scancell Holdings's Net Income for the six months ended in Oct. 2025 was $-7.67 Mil. Scancell Holdings's Revenue for the six months ended in Oct. 2025 was $0.00 Mil. Therefore, Scancell Holdings's net margin for the quarter that ended in Oct. 2025 was 0.00%.

The historical rank and industry rank for Scancell Holdings's Net Margin % or its related term are showing as below:

SCNLF' s Net Margin % Range Over the Past 10 Years
Min: -260.5   Med: -243.48   Max: -116.98
Current: -116.98

SCNLF's Net Margin % is ranked worse than
52.64% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs SCNLF: -116.98

Scancell Holdings  (OTCPK:SCNLF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Scancell Holdings Net Margin % Related Terms

Scancell Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Net Margin % Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -226.45 0.00 -260.47

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 4.91 0.00

SCNLF vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Scancell Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Net Margin % falls into.


SCNLF
20GF Score
Scancell Holdings PLC SCNLF
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Scancell Holdings's Net Margin for the fiscal year that ended in Apr. 2025 is calculated as

Net Margin=Net Income (A: Apr. 2025 )/Revenue (A: Apr. 2025 )
=-16.126/6.191
=-260.47 %

Scancell Holdings's Net Margin for the quarter that ended in Oct. 2025 is calculated as

Net Margin=Net Income (Q: Oct. 2025 )/Revenue (Q: Oct. 2025 )
=-7.666/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Scancell Holdings (SCNLF) has a Net Margin % of 0.00% as of Oct. 2025. Net margin is the ratio of total net income to net sales. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #498 out of 946 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Scancell Holdings' Net Margin % too high?
Scancell Holdings' current Net Margin % is 0.00%. Based on the distribution chart, Scancell Holdings ranks #498 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #498 out of 946 companies for Net Margin %. This places Scancell Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Net Margin % is 0.00% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price